ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,851.70
-0.15%
S&P ASX All Technology
3,077.90
0.70%
Brent Oil
83.08
-0.54%
US Dollar vs AUD
1.49829
-0.04%
Bitcoin
70,457.31
-1.39%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Soligenix Inc (SNGX)

  7. Soligenix Inc (SNGX) News

SNGX

Soligenix (SNGX)

Soligenix Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNGX
DateTimeSourceHeadlineSymbolCompany
21/05/202421:30PR Newswire (US)SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX ConferenceNASDAQ:SNGXSoligenix Inc
20/05/202421:30PR Newswire (US)Soligenix Encourages Stockholders to Vote Prior to Annual MeetingNASDAQ:SNGXSoligenix Inc
18/05/202406:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
18/05/202406:09Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNGXSoligenix Inc
16/05/202421:30PR Newswire (US)Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical PracticeNASDAQ:SNGXSoligenix Inc
16/05/202406:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNGXSoligenix Inc
11/05/202406:16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SNGXSoligenix Inc
11/05/202406:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNGXSoligenix Inc
10/05/202421:30PR Newswire (US)Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial ResultsNASDAQ:SNGXSoligenix Inc
06/05/202421:30PR Newswire (US)Soligenix to Present at Upcoming ConferencesNASDAQ:SNGXSoligenix Inc
25/04/202421:30PR Newswire (US)Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaNASDAQ:SNGXSoligenix Inc
18/04/202422:30PR Newswire (US)Soligenix Announces Pricing of $4.75 Million Public OfferingNASDAQ:SNGXSoligenix Inc
15/04/202421:30PR Newswire (US)FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus InfectionNASDAQ:SNGXSoligenix Inc
11/04/202421:30PR Newswire (US)FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus InfectionNASDAQ:SNGXSoligenix Inc
03/04/202422:30PR Newswire (US)Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines AgencyNASDAQ:SNGXSoligenix Inc
15/03/202422:30PR Newswire (US)Soligenix Announces Recent Accomplishments and Year End 2023 Financial ResultsNASDAQ:SNGXSoligenix Inc
08/02/202423:30PR Newswire (US)Soligenix Announces Formation of Behçet's Disease Medical Advisory BoardNASDAQ:SNGXSoligenix Inc
25/01/202423:30PR Newswire (US)Soligenix to Present at The Microcap ConferenceNASDAQ:SNGXSoligenix Inc
08/01/202423:30PR Newswire (US)FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's DiseaseNASDAQ:SNGXSoligenix Inc
04/01/202423:30PR Newswire (US)Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate PsoriasisNASDAQ:SNGXSoligenix Inc
02/01/202423:30PR Newswire (US)Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg VirusesNASDAQ:SNGXSoligenix Inc
23/12/202308:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
18/12/202316:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SNGXSoligenix Inc
16/12/202308:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
16/12/202308:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
16/12/202308:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
16/12/202308:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
16/12/202308:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
09/12/202309:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
09/12/202309:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
 Showing the most relevant articles for your search:NASDAQ:SNGX

Your Recent History

ASX
BHP
BHP
ASX
WOW
Woolworths
ASX
XJO
S&P ASX 200
NYSE
MCD
McDonalds
ASX
NAB
National Australia Bank
COIN
ETHUSD
Ethereum
ASX
TLS
Telstra
NYSE
DIS
Walt Disney
ASX
RIO
Rio Tinto
PM
XAUUSD
Gold vs US Dollar
NYSE
NKE
Nike
ASX
ORG
Origin Energy
ASX
WDC
Westfield
FX
AUDUSD
AUD vs US Dollar
ASX
CBA
Commonwealth Bank Of Aus...
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved